99 related articles for article (PubMed ID: 26067460)
1. Clinicopathologic features and time interval analysis of contralateral breast cancers.
Liederbach E; Piro R; Hughes K; Watkin R; Wang CH; Yao K
Surgery; 2015 Sep; 158(3):676-85. PubMed ID: 26067460
[TBL] [Abstract][Full Text] [Related]
2. Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohort.
Akdeniz D; Kramer I; van Deurzen CHM; Heemskerk-Gerritsen BAM; Schaapveld M; Westenend PJ; Voogd AC; Jager A; Steyerberg EW; Sleijfer S; Schmidt MK; Hooning MJ
Cancer Med; 2023 Feb; 12(3):3123-3133. PubMed ID: 36127572
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast Cancer.
Liederbach E; Wang CH; Lutfi W; Kantor O; Pesce C; Winchester DJ; Yao K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S412-21. PubMed ID: 26334294
[TBL] [Abstract][Full Text] [Related]
4. Metachronous contralateral breast cancer as first event of relapse.
de la Rochefordière A; Mouret-Fourme E; Asselain B; Scholl SM; Campana F; Broët P; Fourquet A
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):615-21. PubMed ID: 8948346
[TBL] [Abstract][Full Text] [Related]
5. Contralateral breast cancer: factors associated with stage and size at presentation.
Mertens WC; Hilbert V; Makari-Judson G
Breast J; 2004; 10(4):304-12. PubMed ID: 15239788
[TBL] [Abstract][Full Text] [Related]
6. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
7. Contralateral breast cancer: a clinico-pathological study of second primaries in opposite breasts after treatment of breast malignancy.
Shankar A; Roy S; Malik A; Kamal VK; Bhandari R; Kishor K; Mahajan M; Sachdev J; Jeyaraj P; Rath G
Asian Pac J Cancer Prev; 2015; 16(3):1207-11. PubMed ID: 25735357
[TBL] [Abstract][Full Text] [Related]
8. Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular, and favorable histologic subtypes of breast cancer?
Chan SW; LaVigne KA; Port ER; Fey JV; Brogi E; Borgen PI; Cody HS
Ann Surg; 2008 Jan; 247(1):143-9. PubMed ID: 18156934
[TBL] [Abstract][Full Text] [Related]
9. Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen.
Bachleitner-Hofmann T; Pichler-Gebhard B; Rudas M; Gnant M; Taucher S; Kandioler D; Janschek E; Dubsky P; Roka S; Sporn E; Jakesz R
Clin Cancer Res; 2002 Nov; 8(11):3427-32. PubMed ID: 12429630
[TBL] [Abstract][Full Text] [Related]
10. The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy.
Abdalla I; Thisted RA; Heimann R
Cancer J; 2000; 6(4):266-72. PubMed ID: 11038147
[TBL] [Abstract][Full Text] [Related]
11. [Bilateral carcinoma of the breast].
Napolitano L; Grossi S; Cianchetti E
Ann Ital Chir; 1993; 64(6):665-8; discussion 668-9. PubMed ID: 8080156
[TBL] [Abstract][Full Text] [Related]
12. Contralateral breast cancer: clinical characteristics and impact on prognosis.
Healey EA; Cook EF; Orav EJ; Schnitt SJ; Connolly JL; Harris JR
J Clin Oncol; 1993 Aug; 11(8):1545-52. PubMed ID: 8336193
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic mastectomy in patients at high risk: is there a role for sentinel lymph node biopsy?
Murthy V; Chamberlain RS
Clin Breast Cancer; 2013 Jun; 13(3):180-7. PubMed ID: 23357305
[TBL] [Abstract][Full Text] [Related]
14. [Lymph node metastasis and prognostic analysis of 354 cases of T1 breast cancer].
Lyu Z; Wang J; Kang L; Hu C; He H; Guan M; Li J; Guan Y; Song Y
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):382-5. PubMed ID: 25030596
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of breast carcinoma cases with false-negative sentinel lymph nodes.
Wei S; Bleiweiss IJ; Nagi C; Jaffer S
Clin Breast Cancer; 2014 Aug; 14(4):280-4. PubMed ID: 24581736
[TBL] [Abstract][Full Text] [Related]
16. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of lobular breast cancer histology: new insights from a single hospital cross-sectional study and SEER data.
Brouckaert O; Laenen A; Smeets A; Christiaens MR; Vergote I; Wildiers H; Moerman P; Floris G; Neven P;
Breast; 2014 Aug; 23(4):371-7. PubMed ID: 24530094
[TBL] [Abstract][Full Text] [Related]
18. An analysis of prognostic features in infiltrating lobular carcinoma of the breast.
Frost AR; Terahata S; Yeh IT; Siegel RS; Overmoyer B; Silverberg SG
Mod Pathol; 1995 Oct; 8(8):830-6. PubMed ID: 8552571
[TBL] [Abstract][Full Text] [Related]
19. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
20. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
Barth A; Craig PH; Silverstein MJ
Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
